CMS Response to Public Comments for CMS-10798 (OMB 0938-1428), Application for Part B Immunosuppressive Drug Coverage (Part B-ID)

The Centers for Medicare and Medicaid Services (CMS) received a comment on the “Application for Part B Immunosuppressive Drug Coverage (Part B-ID) (CMS–10798, OMB 0938-1428)”, as outlined in the Federal Register (89 FR 104545) dated December 23, 2024, from the state of Washington’s Aging and Long-Term Support Administration (ALTSA). This is the reconciliation of the comments from the 60-day public comment period.

***Comment:*** The commenter agreed that the form and the Part B-ID benefit are beneficial to many individuals. They stated that this allows individuals to have continued access to necessary immunosuppressive drugs to prevent transplant rejection. The commenter mentioned that the form and Part B-ID benefit may be especially useful to Washington PACE participants.

***Response:***  We thank you for your comment and support.